REGN5458
Multiple myeloma
Phase 1/2Active
Key Facts
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a premier biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company has built a diversified portfolio of FDA-approved treatments and maintains a robust pipeline across oncology, immunology, ophthalmology, and other therapeutic areas. Regeneron's proprietary VelociSuite technologies, including VelocImmune mice and advanced manufacturing capabilities, enable rapid drug discovery and development. With multiple billion-dollar commercial products and strong financial performance, Regeneron ranks among the most successful biotech companies globally.
View full company profileTherapeutic Areas
Other Multiple myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |
| YH29407 | Yuhan | Phase 1 |